Pathos AI entered into a strategic collaboration with Bristol Myers Squibb and Tempus AI to develop artificial intelligence tools for drug development in Alzheimer's disease and other neurological conditions.

From the articleAI drug firm Pathos raises $237 million, pushing valuation to $3 billionAlso in Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development | Reuters, AI drug development startup Pathos AI closes $237M investment - SiliconANGLE